Northwest Biotherapeutics (OTCMKTS:NWBO) Posts Quarterly Earnings Results

Northwest Biotherapeutics (OTCMKTS:NWBO) announced its quarterly earnings data on Monday. The biotechnology company reported ($0.02) EPS for the quarter, Zacks reports. The company had revenue of $0.23 million during the quarter.

Northwest Biotherapeutics Stock Performance

Shares of OTCMKTS NWBO traded down $0.02 during trading on Wednesday, hitting $0.21. 3,911,649 shares of the company were exchanged, compared to its average volume of 3,229,775. The company has a fifty day moving average price of $0.26 and a 200-day moving average price of $0.28. The firm has a market capitalization of $293.89 million, a PE ratio of -2.65 and a beta of -0.52. Northwest Biotherapeutics has a 12-month low of $0.20 and a 12-month high of $0.57.

Northwest Biotherapeutics Company Profile

Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer.